Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit

Namur, Julien; Pascale, Florentina; Maeda, Nobuji; Sterba, Manon; Ghegediban, S.; Verret, Valentin; Paci, Angélo; Seck, Atmane; Osuga, Keigo; Wassef, Michel; Reb, Philippe; Laurent, Alexandre

doi:10.1016/j.jvir.2015.03.014

Cited by 17 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 In an in vivo model, HepaSphere® was shown to induce higher local concentration of anticancer drug compared with DC bead. 37 Furthermore, we could not show the differences of antitumor effect between epirubicin and arterial cisplatin in the present study. Anticancer effects with different DEBs or eluting anticancer drugs for c-TACE refractory should be confirmed in further studies.…”

contrasting

confidence: 72%

<p>Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization</p>

Kobayashi

Tajiri

Murayama

et al. 2020

JHC

View full text Add to dashboard Cite

To evaluate the potential of drug-eluting bead (DEB)-transcatheter arterial chemoembolization (TACE) as a treatment option for patients with refractory to conventional lipiodol-based TACE (c-TACE) especially with decreased liver function. Patients and Methods: We retrospectively evaluated the treatment results of DEB-TACE for 89 HCC nodules in 27 patients with c-TACE refractory according to liver function. Results: Although overall survival was significantly better in Child-Pugh A patients than in Child-Pugh B patients (median survival time, MST: 561 vs 347 days, p=0.031), progressionfree survival was almost similar in both patients between Child-Pugh A and B (MST: 79 vs 87 days, p=0.534). Regarding antitumor response, the objective response rate (ORR) and disease-control rate (DCR) were 5.3/12.5% and 52.7/87.5% in Child-Pugh A/B, respectively. In each 89 HCC nodules, ORR and DCR were almost similar between Child-Pugh A and B (ORR, 20.3 vs 13.3%; DCR, 77.0 vs 73.3%, respectively). Adverse events of DEB-TACE were well-tolerated, and liver function was reserved during DEB-TACE procedures. Conclusion: DEB-TACE could be a therapeutic option for advanced HCC patients with c-TACE refractory and decreased liver function.

show abstract

contrasting

confidence: 72%

<p>Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization</p>

Kobayashi

Tajiri

Murayama

et al. 2020

JHC

View full text Add to dashboard Cite

show abstract

“…This study measured plasma pharmacokinetics of irinotecan and its active metabolite SN38 followed by sacrifice of the test animals 3 days post embolization treatment for tissue assessment [108]. Both spheres at the smallest size range available were used.…”

Section: Commercially Available Materialsmentioning

confidence: 99%

Polymeric materials for embolic and chemoembolic applications

Poursaid

Jensen

Huo

et al. 2016

Journal of Controlled Release

113

103

View full text Add to dashboard Cite

Percutaneous transcatheter embolization procedures involve the selective occlusion of blood vessels. Occlusive agents, referred to as embolics, vary in material characteristics including chemical composition, mechanical properties, and the ability to concurrently deliver drugs. Commercially available polymeric embolics range from gelatin foam to synthetic polymers such as poly(vinyl alcohol). Current systems under investigation include tunable, bioresorbable microspheres composed of chitosan or poly(ethylene glycol) derivatives, in situ gelling liquid embolics with improved safety profiles, and radiopaque embolics that are trackable in vivo. This article reviews commercially available materials used for embolization as well as polymeric materials that are under investigation.

show abstract

“…Fifth, there are limited DOX toxicology data for VX2 cells on which to base (8). In 2015, Namur et al reported that embolization with irinotecan-loaded microspheres resulted in greater necrosis in rabbit VX2 tumors than that with microspheres containing no chemotherapy agents (50%-69% vs 22%, respectively), although this difference was not significant (31). From a clinical standpoint, Malagari et al demonstrated superior tumor response with the addition of DOX to DEB therapy in a 2010 prospective randomized study of 84 patients with HCC (10).…”

Section: Power Analysismentioning

confidence: 99%

Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors

Gaba¹,

Emmadi²,

Parvinian³

et al. 2016

Radiology

View full text Add to dashboard Cite

Purpose To quantify the correlation between doxorubicin (DOX) delivery and tumor necrosis after drug-eluting bead (DEB) transarterial chemoembolization (TACE). Materials and Methods In this animal care committee-approved study, New Zealand white rabbit VX2 liver tumors were treated transarterially with DOX-loaded 70-150-μm DEBs in five treatment groups with varying drug doses: sham (saline), 0 mg, 12.5 mg, 25 mg, and 37.5 mg. DEB TACE was followed by 3- and 7-day sacrifice, tumor harvest, and sectioning. Drug delivery was assessed by using fluorescence imaging, and tumor necrosis was quantified by means of histologic analysis. Statistical correlation of DOX delivery and tumor necrosis was performed by using the Spearman rank correlation coefficient (ρ). Results Thirty-six VX2 tumors (median diameter, 1.3 cm) in 20 rabbits (median weight, 2.8 kg) underwent successful DEB TACE. Treatment groups included eight, seven, eight, five, and eight tumors of similar size (P > .05). Tumors showed progressively greater DOX extent (sham, 0%; 0 mg, 0%; 12.5 mg, 3%; 25 mg, 20%; and 37.5 mg, 27%) and intensity (sham, 0.4; 0 mg, 1.9; 12.5 mg, 8.5; 25 mg, 9.6; and 37.5 mg, 18.3) and higher median percentage necrosis (sham, 68%; 0 mg, 64%; 12.5 mg, 76%; 25 mg, 78%; and 37.5 mg, 83%) across DOX treatment groups. Correlation of DOX extent (ρ = 0.975, P = .005) and intensity (ρ = 0.900, P = .037) with percentage tumor necrosis was statistically significant. Conclusion Incremental increases in DOX correlate with greater necrosis in rabbit VX2 liver tumors after DEB TACE. This result indicates an essential role for chemotherapy-induced cytotoxicity in TACE effectiveness and supports the use of chemotherapeutic drugs in transarterial therapy. (©) RSNA, 2016 Online supplemental material is available for this article.

show abstract

Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit

Cited by 17 publications

References 24 publications

<p>Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization</p>

<p>Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization</p>

Polymeric materials for embolic and chemoembolic applications

Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors

Contact Info

Product

Resources

About